EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advancing Obstructive Airway Disease Treatment: Dual PDE3/4 Inhibition as a Therapeutic Strategy

Rinzhin T Sherpa, Cynthia J Koziol-White, Reynold A Panettieri iD

Cells · 2025

DOI: 10.3390/cells14090659 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2025. Verfasst von Rinzhin T Sherpa und 2 weiteren Autor:innen. Beteiligte Einrichtung: Rutgers Institute for Translational Medicine and Science, Rutgers University, 89 French Street, New Brunswick, NJ 08901, USA. Hauptthemen laut MEDLINE: Phosphodiesterase 4 Inhibitors, Pulmonary Disease, Chronic Obstructive, Phosphodiesterase 3 Inhibitors, Asthma. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, National Heart Lung and Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obstructive airway diseases, including asthma and chronic obstructive pulmonary disease (COPD), evoke significant global health concerns manifested by airway inflammation and obstruction. Despite their differing origins, shared pathophysiological features and responses to therapeutic interventions highlight common molecular mechanisms. Standard treatments include inhaled bronchodilators, with combination therapies offering enhanced symptom control. Cyclic AMP (cAMP) plays a crucial role in airway relaxation. Phosphodiesterase (PDE) decreases cAMP levels, thereby attenuating the relaxation of airway smooth muscle, making it a promising therapeutic target. The balance between cAMP production and degradation is essential for regulating airway tone and function. PDE inhibitors for the treatment of obstructive airway diseases have suffered challenges, with adverse side effects of prospective inhibitors causing clinical failures. Efforts to develop PDE inhibitors with an improved safety profile could prove to be beneficial as an add-on treatment for severe asthma and COPD. The recent FDA approval of Ensifentrine, a dual PDE3/4 inhibitor, can significantly advance COPD management by improving bronchodilation, reducing inflammation, and lowering exacerbation rates with favorable safety outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphodiesterase 4 InhibitorsPulmonary Disease, Chronic ObstructivePhosphodiesterase 3 InhibitorsAsthmaCyclic Nucleotide Phosphodiesterases, Type 4HumansAnimalsBronchodilator Agents

Stichwörter der Autor:innen

AsthmaCOPDPDEcAMPensifentrine

Substanzen

Phosphodiesterase 4 InhibitorsPhosphodiesterase 3 InhibitorsCyclic Nucleotide Phosphodiesterases, Type 4Bronchodilator Agents

Autor:innen und Institutionen

  • Rutgers Institute for Translational Medicine and Science, Rutgers University, 89 French Street, New Brunswick, NJ 08901, USA.

ORCID-Profile: Reynold A Panettieri

Förderung

  • NHLBI NIH HHS
  • National Heart Lung and Blood Institute

Zitieren

APA

Sherpa, R. T., Koziol-White, C. J., & Panettieri, R. A. (2025). Advancing Obstructive Airway Disease Treatment: Dual PDE3/4 Inhibition as a Therapeutic Strategy. Cells. https://doi.org/10.3390/cells14090659

Vancouver

Sherpa RT, Koziol-White CJ, Panettieri RA. Advancing Obstructive Airway Disease Treatment: Dual PDE3/4 Inhibition as a Therapeutic Strategy. Cells. 2025. doi:10.3390/cells14090659

BibTeX
@article{Sherpa2025,
  author = {Sherpa, Rinzhin T and Koziol-White, Cynthia J and Panettieri, Reynold A},
  title = {Advancing Obstructive Airway Disease Treatment: Dual PDE3/4 Inhibition as a Therapeutic Strategy},
  journal = {Cells},
  year = {2025},
  doi = {10.3390/cells14090659}
}
Kostenlos starten →